Investors - Press Releases
|View printer-friendly version|
TRHC Launches First Large Simulation Study to Assess Adverse Drug Events with proposed COVID-19 Treatments
“This study showcases the depth and breadth of our clinical research capabilities,” said TRHC Chairman and CEO
In conducting the study,
“Our study allows for simulation of the impact of adding, one at a time, each COVID-19 repurposed drug to the actual drug regimens of a large number of frail, elderly patients with polypharmacy—without exposing them to these drugs, “ states TRHC Chief Scientific Officer
This study will also examine the combined risk of increased ADEs for drug regimens with COVID-19 repurposed adjuvants, especially drug-induced Long QT Syndrome, a disorder that occurs in the heart that can potentially cause fast, chaotic heartbeats, triggering a sudden fainting spell, seizure or in some cases death. The results of this study should be completed and ready for publication within 60 days.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. These forward-looking statements include, among other things, our goals and expectations regarding the combined company and the integration of PW into TRHC, the expected synergies from the combined company and the expected financial and operating performance of TRHC following the completion of the acquisition. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the risk that we may not be able to achieve our expectations for the combined companies due to challenges in integration and inability to retain key employees; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations and pharmacies; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; and the other risk factors set forth from time to time in our filings with the
T: (856) 912-5714
T: (215) 870-0829
T: (312) 451-2157
Source: Tabula Rasa HealthCare, Inc.